Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors

Eckhard Zander, Sabine Herfurth, Beate Bohl, Peter Heinke, Uwe Herrmann, Klaus-Dieter Kohnert and Wolfgang Kerner

doi:10.1136/bjo.84.8.871

Updated information and services can be found at:
http://bjo.bmjjournals.com/cgi/content/full/84/8/871

References
This article cites 34 articles, 15 of which can be accessed free at:
http://bjo.bmjjournals.com/cgi/content/full/84/8/871#BIBL
3 online articles that cite this article can be accessed at:
http://bjo.bmjjournals.com/cgi/content/full/84/8/871#otherarticles

Rapid responses
You can respond to this article at:
http://bjo.bmjjournals.com/cgi/eletter-submit/84/8/871

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Ophthalmology (1569 articles)
Vision Research (670 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to British Journal of Ophthalmology go to:
http://www.bmjjournals.com/subscriptions/
Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors

Eckhard Zander, Sabine Herfurth, Beate Bohl, Peter Heinke, Uwe Herrmann, Klaus-Dieter Kohnert, Wolfgang Kerner

Abstract

Aim—To examine possible relation between diabetic maculopathy and various risk factors for diabetic complications in patients with diabetes mellitus type 1 and type 2.

Methods—Cross sectional study of two cohorts of diabetic patients, comprising 1796 patients with type 1 diabetes (mean age 47 years, mean duration of diabetes 24 years) and 1563 patients with type 2 diabetes (mean age 62 years, mean duration of diabetes 16 years). Retinopathy levels (R0–RV) and maculopathy were assessed by fluorescence angiography and fundus photography and binocular biomicroscopy. Diabetic neuropathy was assessed by means of computer assisted electrocardiography and by thermal and vibratory sensory examination. Patients were classified as normoalbuminuric (<20 µg/min) or microalbuminuric (20–200 µg/min) according to their albumin excretion rates measured in urine collected overnight. Using univariate analyses, the effects of selected patient characteristics on the presence of maculopathy were evaluated. Multiple logistic regression analyses were performed to determine independent effects of risk variables on diabetic maculopathy.

Results—Background retinopathy (RII) was found to be present in 28% of type 1 diabetic patients and in 38% of type 2 diabetic patients. The prevalence of maculopathy in these patients was remarkably high (42% in type 1 and 53% in type 2 diabetic patients). Patients with maculopathy had significantly impaired visual acuity. Multiple logistic correlation analysis revealed that in both types of diabetes maculopathy exhibited independent associations with duration of diabetes and with neuropathy (p <0.01); in type 1 diabetic patients there were significant associations with age at diabetes onset, serum triglyceride and total cholesterol levels (p <0.05); in type 2 diabetes with serum creatinine levels and with hypertension (p <0.05).

Conclusions—Irrespective of the type of diabetes, diabetic patients with longstanding diabetes have a high risk for the development of diabetic maculopathy. Diabetic maculopathy is closely associated with diabetic nephropathy and neuropathy and with several atherosclerotic risk factors which suggests that these factors might have an important role in the pathogenesis of maculopathy. However, prospective trials are necessary to evaluate the predictive value of such factors. The findings of the present cross sectional study reinforce the arguments of previous studies by others for tight control of hypertension and hyperglycaemia.

Diabetic retinopathy is the most common microvascular complication in diabetes which can produce severe visual loss. The pathogenetic mechanisms involved in the onset and progression of retinopathy are poorly understood. Independent of diabetic retinopathy, severe visual impairment among diabetic patients may also be caused by diabetic maculopathy. Diabetic maculopathy, resulting from diabetic retinopathy, is defined as the presence of retinal thickening within one disc diameter or two of the macula.

Macular oedema results from the accumulation of fluid at the posterior pole of the retina and visual acuity is threatened if the retina in the centre of the macula is thickened. Factors associated with the development of maculopathy are mostly unknown. Since diabetic maculopathy is characterised by increased capillary leakage in the main retinal vessels and by alterations in the microcirculation of the macula, several previous reports have suggested that poor metabolic control might be involved in haemodynamic changes of retinal circulation, and thereby lead to maculopathy. It is conceivable that increases in the retinal blood flow could play a part in haemodynamic changes of increased intracapillary retinal pressure and shear stress, thereby leading to diabetic maculopathy.

Most studies about diabetic maculopathy and associated risk factors are hospital based cohort studies. There is only one population based cohort study which was extended to a longitudinal study. Recent data have shown that better glycaemic and blood pressure control are beneficial in reducing the incidence of macular oedema.

It was the aim of present cross sectional study (1) to determine the prevalence of diabetic maculopathy in both type 1 and type 2 diabetic patients and (2) to study the associations between diabetic maculopathy and different risk factors.

Research design and methods

PATIENTS

The present cross sectional study, based on the total clinic population, included 1796 non-selected type 1 diabetic patients and 1563 type...
2 diabetic patients with and without insulin treatment, attending our hospital during 1995 and 1996. All patients were white people residing in the northeastern region of Germany. Diagnosis of type 1 or type 2 diabetes was made by clinical judgment (age at diagnosis; start of insulin treatment during the first year after diagnosis). When diagnosis was uncertain, the result of C peptide measurement was included into diagnostic decision. Clinical characteristics of the patients studied are shown in Table 1. All patients gave their informed consent and signed an agreement for diagnosis, assessments, photographs, and fluorescein angiography according to the declarations of Helsinki and Hong Kong.

STUDY DESIGN

Assessment of diabetic retinopathy

Ophthalmoscopic examinations in all patients were carried out by two experienced ophthalmologists. Grading of diabetic retinopathy was done after ophthalmoscopy with dilated pupils and drawing the ophthalmoscopic picture and by fluorescein angiographic investigation. Retinopathy was determined according to Seidelin and Herfurth and was classified as follows:

- R0 = without retinopathy
- RI = microaneurysms only
- RII = minimal retinal haemorrhages, hard and/or soft exudates (cotton wool exudates, several microaneurysms) = background retinopathy
- RIII = new vessels and/or fibrous proliferations without involving corpus vitreous
- RIV = papillary neovascularisation, proliferative retinopathy involving corpus vitreous with rubecosis iridis
- RV = blindness due to diabetic retinopathy (visus <0.15 = 6/90).

Assessment of diabetic maculopathy

Clinically significant diabetic maculopathy was defined in accordance with the ETDR Study and by the presence of a set of characteristics:

- Retinal thickening at or within 500 µm of the centre of the macula.
- Macular oedema.
- Hard exudates at or within 500 µm of the macula, if associated with thickening of adjacent retina, or
- A zone, or zones, of retinal thickening one disc diameter or larger, any part of which is within one disc diameter of the centre of the macula.

Examinations of diabetic maculopathy were carried out by ophthalmologists by stereo slit lamp biomicroscopy, fundus photography, and fluorescein angiography. It should be noted that diabetic macular oedema is only one of the alterations of the macula and this term is not synonymous with diabetic maculopathy. Diabetic maculopathy includes focal macular oedema, diffuse macular oedema, cystoid macular oedema, exudative macular oedema, ischaemic maculopathy, and macular oedema of proliferative diabetic retinopathy.

Table 1: Clinical characteristics of type 1 and type 2 diabetic patients

<table>
<thead>
<tr>
<th></th>
<th>Type 1 diabetes (n = 1796)</th>
<th>Type 2 diabetes (n = 1563)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RII–IV</td>
<td>RV</td>
</tr>
<tr>
<td></td>
<td>without MP</td>
<td>with MP</td>
</tr>
<tr>
<td>No of patients</td>
<td>1101 (406)</td>
<td>269 (20)</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>28.3 (4.4)</td>
<td>44.3 (0.6)</td>
</tr>
<tr>
<td>Age at manifestation (years)</td>
<td>19.4 (0.2)</td>
<td>26.6 (0.5)</td>
</tr>
<tr>
<td>AER (µg/min)</td>
<td>23.2 (3.1)</td>
<td>131.4 (16.2)</td>
</tr>
<tr>
<td>Creatinine (µmol/l)</td>
<td>73.3 (0.7)</td>
<td>88.0 (2.6)</td>
</tr>
<tr>
<td>Tg (mmol/l)</td>
<td>1.5 (0.05)</td>
<td>1.5 (0.05)</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.2 (0.04)</td>
<td>5.8 (0.06)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.7 (0.06)</td>
<td>8.5 (0.09)</td>
</tr>
</tbody>
</table>

Data represent means (SEM) and differences between RII–IV with maculopathy and RII–RIV without maculopathy (MP) significant at p <0.05 and p <0.01, respectively.

Significance **p <0.01; *p <0.05.

n = total number of patients in each cohort.
Diabetic maculopathy and risk factors

873

Type 1 diabetes: (1)

Assessment of diabetic nephropathy

Diabetic nephropathy was diagnosed when albumin excretion rates exceeded 200 µg/min and/or serum creatinine levels exceeded 102 µmol/l in male and 88 µmol/l in female patients, respectively. Normoalbuminuria was defined as albumin excretion rate < 20 µg/min, microalbuminuria as albumin excretion rate between 20.0 and 200 µg/min.

Biochemical methods

Urinary albumin excretion rates (UAE) were measured by immunoturbidimetric method (Cobas Mira, Hoffmann La Roche AG) in urine samples collected on three occasions from 10 pm to 6 am. Serum for measurement of cholesterol (CHOD-PAP method), triglycerides (GPO-PAP method), HDL-cholesterol (phosphotungstate magnesium method), and creatinine (Jaffé method) was prepared from blood samples drawn after an overnight fast; measurements were performed with a Hitachi-911 analyser (Hoffmann La Roche AG) or Cobas Mira Analyser (Hoffmann La Roche AG). Serum C peptide was measured by ELISA (Dako-Diagnostica GmbH) in fasting serum samples. HbA1c was measured in haemolysed EDTA-blood by HPLC method (Diamat, Bio-Rad Laboratories).

Statistical methods

Data are presented as means (SEM). Statistical significance was tested by t test or \( \chi^2 \) test as indicated in the corresponding tables. Stepwise multiple logistic regression analysis (SPSS, Version 9.0) was applied to evaluate the impact of each category compared with reference category of low levels.

Results

The prevalence of diabetic maculopathy was determined to be 15% in patients with type 1 and 23% in patients with type 2 diabetes. In type 1 diabetic patients 28% (500/1769) had background retinopathy. In those patients with background retinopathy 42% (208/500) had diabetic maculopathy. Among type 1 diabetic patients 10% (175/1796) were suffering from proliferative retinopathy and, of those, 35% (61/175) had diabetic maculopathy. In type 2 diabetic patients 38% (598/1563) had background retinopathy and 53% (315/598) diabetic maculopathy. In the group of type 2 diabetic patients (5%; 84/1563) with proliferative retinopathy 56% (47/315) had diabetic maculopathy. Type 1 diabetic patients with maculopathy were characterised by higher mean serum creatinine (99.4 (4.5) versus 88.0 (2.6) µmol/l; p<0.01), higher mean triglyceride (1.9 (0.1) versus 1.5 (0.1) mmol/l; p<0.05), and higher mean serum cholesterol levels (6.2 (0.1) versus 5.8 (0.1) mmol/l; p<0.01) than those patients without maculopathy (Table 1).

In type 2 diabetic patients no such differences were found and, as in the in the type 1 diabetic cohort, there were neither differences in mean albumin excretion rates nor in HbA1c, levels between patients with and without diabetic maculopathy (Table 1). Visual acuity decreased with increasing severity of diabetic retinopathy (p<0.01) in type 1 and type 2 diabetic patients (Table 2). In either type of diabetes with maculopathy, the distribution between retinopathy levels was similar for both eyes. Prevalence rates of maculopathy in cohorts with type 1 and type 2 diabetes were found to increase consistently with diabetes duration up to 30 years (Table 3), but tended to be higher in type 2 than in type 1 diabetes. No relation was found between the prevalence of maculopathy and levels of glycosylated haemoglobin. Compared with patients without diabetic maculopathy, increased prevalences in either type of diabetes were associated with hypertension, nephropathy, and neuropathy (Table 3). Multiple regression analysis, performed to evaluate whether maculopathy was independently associated with characteristic variables or other diabetic complications (Table 4), revealed significant associations with the presence of peripheral and/or autonomic neuropathy (p<0.01) in both type 1 and type 2 diabetic patients. Another independent association included diabetes duration (p<0.01). Differences in associations of maculopathy and patient characteristics were found between type 1 and type 2 diabetic patients. In the type 1 diabetic cohort, maculopathy was positively associated with the age at disease onset (p<0.05), increased triglyceride levels (p<0.05), and increased cholesterol levels (p<0.05). Non-significant associations included increased creatinine levels and hypertension. In contrast, the type 2 diabetic cohort exhibited independent associations of macu-

Table 2  Impact of retinopathy and maculopathy (MP) on visual acuity in diabetic patients

<table>
<thead>
<tr>
<th>Level of diabetic retinopathy</th>
<th>Type 1 diabetes (n = 1796)</th>
<th>Type 2 diabetes (n = 1563)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Right-</td>
<td>Left</td>
</tr>
<tr>
<td>(a) 0/I</td>
<td>0.90 (0.18)**</td>
<td>0.90 (0.18)**</td>
</tr>
<tr>
<td>(b) II–IV without MP</td>
<td>0.72 (0.29)**</td>
<td>0.73 (0.27)**</td>
</tr>
<tr>
<td>(c) II–IV with MP</td>
<td>0.62 (0.28)**</td>
<td>0.59 (0.30)**</td>
</tr>
<tr>
<td>(d) V</td>
<td>0.30 (0.40)</td>
<td>0.22 (0.33)</td>
</tr>
</tbody>
</table>

Data are means (SD); n= number of patients.

Significance: **p<0.01.

Type 1 diabetes: (1) v b, c, d, (2) v c, d, (3) v d. Type 2 diabetes: (1) v a, (2) v a, b, (3) v a, b, c.
The prevalence rates (%) for patients without maculopathy are given in parentheses for comparison. The prevalence rates of diabetic maculopathy with elevated serum creatinine levels (p<0.05) and hypertension (p <0.05), while non-significant associations included age at disease onset, serum triglyceride, and cholesterol levels.

**Discussion**

The present cross sectional study shows that maculopathy occurs frequently in type 1 and type 2 diabetic patients. Prevalence was higher in type 2 than in type 1 diabetic patients. The majority of these patients suffered from background retinopathy. In type 2 diabetes with proliferative retinopathy, the proportion of patients with maculopathy is found to be higher than in type 1 diabetes with proliferative retinopathy. Since the data of the present cross sectional study were obtained from a selected patient population, they cannot directly be compared with data from population based epidemiological studies. Nevertheless, it is noteworthy that the prevalence of proliferative retinopathy in our study was found to be 10% in type 1 diabetic patients and 5% in type 2 diabetic patients. These data match with findings of the Wisconsin Epidemiologic Study of Diabetic Retinopathy, where the overall incidence of retinopathy was reported to be 10% and 7% among the younger and older onset group. The prevalence of background retinopathy in our study is rather high, 28% in type 1 and 38% in type 2 diabetic patients. Furthermore, the prevalence of maculopathy in our type 1 diabetic cohort is 15% and in the type 2 diabetic cohort 23%, whereas the prevalence of macular oedema of the Wisconsin Epidemiologic Study of Diabetic Retinopathy was reported to be 11% in the younger onset group and 8% in the older onset group. The prevalence rates we found are higher than those from population based studies because of patient selection. However, other cross sectional and clinical studies have reported similar frequencies for diabetic maculopathy to our study. In most previous studies, higher rates of macular oedema were found in the presence of non-proliferative retinopathy in older compared with younger onset patients. The majority of our patients with retinopathy had background retinopathy. Among these patients the proportion of diabetic maculopathy is 42% in the type 1 diabetic and 53% in the type 2 diabetic cohort. The proportion of maculopathy is similarly high in those patients with proliferative retinopathy, being 35% and 56% for type 1 and type 2 diabetic patients. In either type of diabetes the presence of maculopathy is associated with diabetes duration and in type 1 diabetic subjects with older age at disease manifestation. These findings are consistent with the Wisconsin Epidemiologic Study of Retinopathy data, demonstrating an increased prevalence of diabetic maculopathy of 28% in patients whose age at the time of diagnosis was 30 years or older and whose diabetes duration was 20 years or longer. In these cases the presence of macular oedema was associated with longer duration of diabetes, higher systolic blood pressure, higher levels of glycosylated haemoglobin and with the presence of proteinuria.

Our data collected from large cohorts of hospital patients confirm the impact of diabetic maculopathy on visual acuity. Regardless of the type of diabetes, the visual acuity of patients with maculopathy is significantly impaired compared with patients without maculopathy, although at identical stages of diabetic retinopathy. After 14 years of observation the Wisconsin Epidemiologic Study of Diabetic Retinopathy showed an incidence of macular oedema of 26% in a cohort of insulin taking diabetic patients diagnosed before the age of 30 years. Furthermore, increased risk of proliferative retinopathy or incidence of macular oedema was found to be associated with more baseline retinopathy, higher baseline HbA1c, and increases in HbA1c levels during the follow up period. When hypertension was present at baseline it was associated with a 91% increase in the risk of proliferative retinopathy, while the presence of gross proteinuria at baseline was associated with a 95% increase in the risk of developing macular oedema. These data together with our present observation demonstrate that factors such as high HbA1c levels, high blood pressure, and proteinuria might contribute to macular oedema formation.

### Table 3: Prevalence of different risk variables in type 1 and type 2 diabetes with maculopathy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Type 1 diabetes (n=1796)</th>
<th>Type 2 diabetes (n=1563)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at manifestation (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–19</td>
<td>12.1</td>
<td>10.2</td>
</tr>
<tr>
<td>20–39</td>
<td>19.7</td>
<td>29.4</td>
</tr>
<tr>
<td>40–59</td>
<td>18.7</td>
<td>25.0</td>
</tr>
<tr>
<td>&gt;60</td>
<td>11.5</td>
<td>9.3</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–9</td>
<td>1.5</td>
<td>6.0</td>
</tr>
<tr>
<td>10–19</td>
<td>16.4</td>
<td>27.6</td>
</tr>
<tr>
<td>20–29</td>
<td>30.7</td>
<td>45.2</td>
</tr>
<tr>
<td>&gt;30</td>
<td>28.1</td>
<td>37.2</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;6.5</td>
<td>15.3 (3.1)</td>
<td>19.1 (8.0)</td>
</tr>
<tr>
<td>&gt;6.0</td>
<td>14.7 (23.3)</td>
<td>18.6 (23.3)</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;2.2 mmol/l</td>
<td>21.9 (13.8)</td>
<td>23.1 (21.3)</td>
</tr>
<tr>
<td>Chol &gt;6.5 mmol/l</td>
<td>26.0 (12.4)</td>
<td>24.4 (22.2)</td>
</tr>
</tbody>
</table>

The prevalence rates (%) for patients without maculopathy are given in parentheses for comparison.

### Table 4: Multiple logistic correlation analysis (odds ratios) for maculopathy in type 1 and type 2 diabetes

<table>
<thead>
<tr>
<th>Variable</th>
<th>Type 1 diabetes (n=1796)</th>
<th>Type 2 diabetes (n=1563)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at manifestation (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–60</td>
<td>2.1*</td>
<td>5.0*</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10–20</td>
<td>9.1**</td>
<td>3.7**</td>
</tr>
<tr>
<td>20–30</td>
<td>15.3**</td>
<td>7.2**</td>
</tr>
<tr>
<td>&gt;30</td>
<td>10.1**</td>
<td>5.3**</td>
</tr>
<tr>
<td>Tg &gt;2.2 mmol/l</td>
<td>1.5*</td>
<td></td>
</tr>
<tr>
<td>Chol &gt;6.5 mmol/l</td>
<td>1.6*</td>
<td>1.3*</td>
</tr>
<tr>
<td>Elevated creatinine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral and/or autonomic neuropathy</td>
<td>3.5**</td>
<td>3.1**</td>
</tr>
</tbody>
</table>

Significance: **p <0.01, *p <0.05, n = number of patients.
Owing to the cross-sectional nature of our data, relations that have been established from prospective studies—for example, between the incidence of macular oedema and glycaemic control,19 could not be identified in our study. However, we found diabetic maculopathy in either type of diabetes to be independently associated with disease duration and thus with exposure to hyperglycaemia. Our study also shows significant associations of maculopathy with increased lipid levels in type 1 diabetic patients and with diabetic nephropathy and hypertension in type 2 diabetic patients. Even though we have not studied haemodynamic changes of the retina circulation in our patients, the present findings are consistent with data in the literature, providing evidence that increased arterial perfusion along with tissue hypoxia could produce macular oedema by exacerbating breakdown of the blood-retinal barrier.17 28 29 In line with the association between diabetic maculopathy and nephropathy in type 2 diabetes is the higher frequency of macular oedema found by others in nephropathic diabetic patients with proteinuria.30 31 It is of particular interest that our study shows significant associations between maculopathy and nephropathy, taking into account peripheral as well as cardiovascular autonomic neuropathy. As with other diabetic complications, neuropathy in type 1 diabetes30 31 and maculopathy30 shows associations with disease duration. On the other hand in a previous cross-sectional study we found cardiovascular autonomic neuropathy to be closely related to diabetic retinopathy.52 This suggests that there may be a causal pathogenetic relation between these two microvascular complications. Although prospective epidemiological studies are needed to clarify whether or not neuropathy is predictive of diabetic retinopathy,35 there are clinical and experimental data, suggesting direct effects of autonomic nervous system on retinal blood flow24 34 35 and the occurrence of blood flow changes in diabetic retinopathy.36 38 These observations support the hypothesis of haemodynamic alterations as important factors in the pathogenesis of diabetic microangiopathy19 and diabetic maculopathy. Diabetic neuropathy could be implicated in the development of these complications, but it needs prospective clinical trials to confirm such a hypothesis. However, the underlying causes of diabetic maculopathy remain to a certain extent speculative and, definitively, nothing can be said without perfusion pressure measurements of retinal circulation. In summary, our present data are consistent with observations from a number of other studies25 38 39 underlining the need for better glycaemic and blood pressure control in order to reduce the incidence of macular oedema and/or the progression of diabetic retinopathy. In addition, our data support the necessity of treating all type 1 and type 2 diabetic patients aggressively to achieve near normal glycaemic, lipid, and blood pressure values.


www.bjophthalmol.com